<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45001">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520466</url>
  </required_header>
  <id_info>
    <org_study_id>EK2012-0201</org_study_id>
    <nct_id>NCT02520466</nct_id>
  </id_info>
  <brief_title>Cocoa Flavanol and Coronary Vasomotion Vascular Function in Patients With Coronary Artery Disease</brief_title>
  <official_title>Effect of Cocoa Flavanol-containing Drink on Coronary Vascular Function in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate whether the ingestion of a cocoa
      flavanol-containing drink compared to a flavanol-free drink, improves coronary vasomotion
      and platelet function in patients with overt coronary artery disease acutely (after 2 hours)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>coronary endothelial function as assessed as response to cold pressor test</measure>
    <time_frame>2 hours</time_frame>
    <description>Primary endpoint will be the improvement in coronary endothelial function in response to cold pressor testing (i.e. % reduction in coronary artery constriction compared to baseline) 2h after ingestion of a cocoa flavanol rich-drink or placebo drink, respectively.
In a subset of patients daily consumption of a flavanol-drink will be assessed and outcomes measured after 3-4 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Stable Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>flavanol-containing drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flavanol-containing drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flavanol-free drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>flavanol-free drink</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavanol-rich drink vs flavanol-free drink</intervention_name>
    <arm_group_label>flavanol-containing drink</arm_group_label>
    <arm_group_label>flavanol-free drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with coronary artery disease undergoing elective coronary angiography with or
        without the need of coronary intervention

          -  Age 20 - 80

          -  Written obtained informed consent

        Exclusion Criteria:

          -  Acute ST-elevation myocardial infarction

          -  Acute non-ST-elevation myocardial infarction (enzyme positive)

          -  Ventricular tachy-arrythmias or AV-Block &gt;I°

          -  Renal insufficiency (GFR MDRD &lt; 30ml/min) or liver disease (ALT or AST &gt;150 IU)

          -  Pregnancy

          -  Known allergy to compounds of cocoa product

          -  Known allergy to contrast media

          -  Known allergy to nuts

          -  Intolerance to coffein and theobromin

          -  Acute infectious disease

          -  Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)

          -  Participation in another study within the last month

          -  Concomitant vitamin supplements and herbal remedies, as well as fruit and tea
             extracts

          -  No study visits ± 1 week before Eastern, Christmas and New Year holyday (altered
             eating habits)

          -  Extreme eating habits (as assessed by a questionnaire)

          -  Alcohol or drug abuse

          -  Lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Lüscher, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Cardiovascular Center Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas F Lüscher, Prof MD</last_name>
    <phone>0041442552121</phone>
    <email>thomas.luscher@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabella Sudano, MD PhD</last_name>
    <phone>0041 44 255 5841</phone>
    <email>isabella.sudano@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Center Cardiology Univeristy Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universisty Hospital of Zurich, Cardiovascular Center Cardiology</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>August 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
